- Home
- CIFR vs EXEL Comparison
CIFR vs EXEL Comparison
Compare CIFR & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CIFR | EXEL |
|---|---|---|
| Founded | 2021 | 1994 |
| Country | United States | United States |
| Employees | 66 | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.3B | 11.4B |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | CIFR | EXEL |
|---|---|---|
| Price | $25.41 | $54.66 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 21 |
| Target Price | $24.91 | ★ $46.50 |
| AVG Volume (30 Days) | ★ 22.4M | 2.5M |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 57.95 |
| EPS | N/A | ★ 0.79 |
| Revenue | N/A | ★ $452,477,000.00 |
| Revenue This Year | $12.29 | $13.61 |
| Revenue Next Year | $240.53 | $13.13 |
| P/E Ratio | ★ N/A | $67.38 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.29 | $33.76 |
| 52 Week High | $30.14 | $53.93 |
Technical Indicators
Market Signals| Indicator | CIFR | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 52.91 | 65.70 |
| Support Level | $13.20 | $40.17 |
| Resistance Level | $25.52 | N/A |
| Average True Range (ATR) | 2.49 | 1.52 |
| MACD | -0.14 | -0.04 |
| Stochastic Oscillator | 48.03 | 90.23 |
Price Performance
Historical ComparisonAbout CIFR Cipher Mining Inc.
Cipher Digital Inc is focused on high-performance computing (HPC) data center development and operations. It is engaged in developing and operating data centers designed for HPC workloads. Its operations include managing power assets and capital allocation in response to market conditions and demand for AI-related computing capacity.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.